Middle East & Africa T Cell Therapy Market

The Middle East & Africa T cell therapy market was valued at US$ 73.14 million in 2022 and is expected to reach US$ 211.46 million by 2030; it is estimated to grow at a CAGR of 14.2% from 2022 to 2030.

Rising Number of CAR T-Cell Therapies in Clinical Trials Fuels the Middle East & Africa T Cell Therapy Market

The current landscape for CAR T-cell therapies across the globe is promising, with multiple drug approvals, a rich pipeline, and many ongoing clinical trials. Pipelines of CAR T-cell therapies are in various stages of clinical development; major pharmaceutical companies are working to advance the pipeline space and future growth potential of the CAR T-cell therapy competitive domain.

•   In November 2022, Peter MacCallum Cancer Centre and Cartherics Pty Ltd entered into a Collaborative Development Program Agreement (CDPA) to develop Cartherics’ proprietary autologous CAR T cell therapy (CTH-001) for treating cutaneous T-cell lymphoma (CTCL). The key aspects of the collaborative research are setting up clinical-scale manufacturing of CTH-001 and conducting a Phase I clinical trial. It will initially enroll six patients with refractory CTCL.

•   JW Therapeutics drug JWCAR029 is a CAR T cell product that targets CD19 and is intended to treat advanced lymphoma and leukemia. The molecule is currently in Phase II of development. JWCAR029 is initially being investigated for treating B-cell malignancies, focusing on relapsed and refractory DLBCL.

•   Gilead Sciences drug KTE-X19 is an autologous CD19 CAR T-cell therapy under investigation. The drug is manufactured using the XLP process, including T-cell selection and lymphocyte enrichment. Lymphocyte enrichment is required in certain B-cell malignancies for which KTE-X19 is being studied. KTE-X19 is currently in Phase II clinical trials for the treatment of both adult and pediatric acute lymphocytic leukemia. The FDA has approved Brexucabtagene autoleucel (formerly KTE-X19; Tecartus) for treating adult patients with relapsed or refractory mantle cell lymphoma (MCL).

•   ZUMA-3 is a Phase 1/2 study evaluating KTE-X19, an autologous anti-CD19 CAR T-cell therapy, in adult relapsed/refractory (R/R) B-cell acute lymphoblastic leukemia (B-ALL).

•   Descartes-11, a mRNA CAR T-cell therapy, has moved into a Phase II clinical trial for newly diagnosed, high-risk multiple myeloma (MM) patients. Descartes-11 expresses CAR T-cell molecules transiently and avoids some characteristic toxicities of these therapeutic agents. A Phase I study (NCT03994705) of 18 patients has already been undertaken, and results showed no evidence of cytokine release syndrome or neurotoxicity—adverse events commonly associated with CAR T-cell treatment.

Thus, the pipelines above for CAR T-cell therapies are emerging as a new trend in the Middle East & Africa T-cell therapy market.

Middle East & Africa T Cell Therapy Market Overview

The T-cell therapy market in the Middle East & Africa is segmented into Israel, Saudi Arabia, South Africa, and the Rest of Middle East & Africa. The T-cell therapy market in the Middle East & Africa is anticipated to grow due to the approval of CAR T-cell therapies and increasing healthcare expenditure. In September 2022, Gilead and Kite established a fully functional cell therapy business unit after the regulatory approval of T-cell therapies such as Yescarta and Tecartus. T-cell therapies will soon be available for the Saudi Arabian population. According to an article published by the National Library of Medicine, CAR T-cell therapy is not yet approved in the UAE; however, it is expected to be approved within the next 2 years.

 Middle East & Africa T Cell Therapy Market Revenue and Forecast to 2030 (US$ Mn)

Middle East & Africa T Cell Therapy Market Segmentation 

The Middle East & Africa T cell therapy market is segmented into modality, therapy type, indication, and country.

Based on modality, the Middle East & Africa T cell therapy market is bifurcated into research and commercialized. The commercialized segment held a larger market share in 2022.

Based on therapy type, the Middle East & Africa T cell therapy market is divided into CAR T-cell therapy and T-cell Receptor (TCR)-based. The CAR T-cell therapy segment held a larger market share in 2022.

Based on indication, the Middle East & Africa T cell therapy market is bifurcated into hematologic malignancies and solid tumors. The hematologic malignancies segment held the largest market share in 2022.

Based on country, the Middle East & Africa T cell therapy market is segmented into Saudi Arabia, Israel, and Rest of Middle East & Africa. Saudi Arabia dominated the Middle East & Africa T cell therapy market in 2022.

Bristol-Myers Squibb Co, Gilead Sciences Inc, Janssen Global Services LLC, Legend Biotech Corp, and Novartis AG are some of the leading companies operating in the Middle East & Africa T cell therapy market.   

Middle East & Africa T Cell Therapy Market Strategic Insights

Middle East & Africa T Cell Therapy Market Segmentation Analysis

Middle East & Africa T Cell Therapy Market Report Highlights

Middle East & Africa T Cell Therapy Report Scope

Middle East & Africa T Cell Therapy Market Country and Regional Insights